Early Antibiotic Exposure and Risk of Childhood Obesity in Latinos

Annette P Ville1, Melvin B Heyman1, Rosalinda Medrano1

  • 1Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Francisco , San Francisco, CA.

Childhood Obesity (Print)
|February 7, 2017
PubMed

Insights

Early antibiotic exposure before six months of age was linked to a higher risk of rapid infant weight gain and obesity by age two in a high-risk cohort. These findings support judicious antibiotic use in infants.

Area of Science:

  • Pediatric Health
  • Nutritional Science
  • Epidemiology

Background:

  • Early life exposures can influence long-term health outcomes.
  • Antibiotic use in infancy is common but potential long-term effects require further investigation.
  • Obesity is a growing public health concern, particularly in high-risk populations.

Purpose of the Study:

  • To examine the association between early antibiotic exposure (before 6 months) and the risk of obesity at 2 years of age.
  • To investigate the relationship in a high-risk, low-income, urban Latino cohort.
  • To provide evidence for antibiotic stewardship in pediatric care.

Main Methods:

  • Prospective cohort study with 97 participants.
  • Data collection included maternal reports of infant dietary intake and food frequency questionnaires.
  • Antibiotic use, infant weight gain, and obesity at age 2 were assessed. Cord blood leptin and insulin levels were measured at birth.
  • Statistical analyses included Chi-squared tests, Student's t-tests, and multivariable logistic regression.

Main Results:

  • Early antibiotic exposure before 6 months was independently associated with increased risk for rapid infant weight gain (OR 6.42, 95% CI 1.17-35.06).
  • Early antibiotic exposure before 6 months was also independently associated with an increased risk for obesity at age 2 (OR 6.15, 95% CI 1.03-36.70).
  • Findings highlight a significant link between early antibiotic use and later obesity risk.

Conclusions:

  • Early antibiotic exposure in the first 6 months of life is a significant risk factor for rapid infant weight gain and obesity by age 2.
  • These results underscore the importance of antibiotic stewardship to minimize infant exposure.
  • Further research is warranted to explore the mechanisms underlying this association.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
335
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
583